Search Results Search Sort by RelevanceMost Recent Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056. Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Policy Forum Sep 2016 Overcoming Historical Separation between Oral and General Health Care: Interprofessional Collaboration for Promoting Health Equity Lisa Simon, DMD Health equity requires physician-dentist collaboration. What are next steps for integrating oral and general health care? AMA J Ethics. 2016;18(9):941-949. doi: 10.1001/journalofethics.2016.18.9.pfor1-1609. Policy Forum Jun 2003 Diversity and the Road to the "Land of Best Care" Lonnie R. Bristow, MD Virtual Mentor. 2003;5(6):225-227. doi: 10.1001/virtualmentor.2003.5.6.pfor1-0306. Policy Forum Jun 2014 Minority-Group Recruitment Goals in Federally Funded Clinical Research: What’s in a Number? Raegan W. Durant, MD, MPH When identifying underrepresented subgroups deserving of special recruitment efforts for research participation, social determinants of health other than race should be given more consideration. Virtual Mentor. 2014;16(6):467-471. doi: 10.1001/virtualmentor.2014.16.6.pfor1-1406. Policy Forum May 2013 Pain and Ethnicity Ronald Wyatt, MD, MHA Biological and cultural differences affect the experience of pain, and misinformation and biases affect its treatment. Virtual Mentor. 2013;15(5):449-454. doi: 10.1001/virtualmentor.2013.15.5.pfor1-1305.
Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Policy Forum Sep 2016 Overcoming Historical Separation between Oral and General Health Care: Interprofessional Collaboration for Promoting Health Equity Lisa Simon, DMD Health equity requires physician-dentist collaboration. What are next steps for integrating oral and general health care? AMA J Ethics. 2016;18(9):941-949. doi: 10.1001/journalofethics.2016.18.9.pfor1-1609.
Policy Forum Jun 2003 Diversity and the Road to the "Land of Best Care" Lonnie R. Bristow, MD Virtual Mentor. 2003;5(6):225-227. doi: 10.1001/virtualmentor.2003.5.6.pfor1-0306.
Policy Forum Jun 2014 Minority-Group Recruitment Goals in Federally Funded Clinical Research: What’s in a Number? Raegan W. Durant, MD, MPH When identifying underrepresented subgroups deserving of special recruitment efforts for research participation, social determinants of health other than race should be given more consideration. Virtual Mentor. 2014;16(6):467-471. doi: 10.1001/virtualmentor.2014.16.6.pfor1-1406.
Policy Forum May 2013 Pain and Ethnicity Ronald Wyatt, MD, MHA Biological and cultural differences affect the experience of pain, and misinformation and biases affect its treatment. Virtual Mentor. 2013;15(5):449-454. doi: 10.1001/virtualmentor.2013.15.5.pfor1-1305.